Details of Xenobiotics-DME Interaction (XEOTIC)

General Information of Drug-Metabolizing Enzyme (DME ID: DME0021)
DME Name Mephenytoin 4-hydroxylase (CYP2C19), Homo sapiens DME Info
UniProt ID
CP2CJ_HUMAN
EC Number    EC: 1.14.14.1     (Click to Show/Hide the Complete EC Tree)
Oxidoreductase
Oxygen paired donor oxidoreductase
Flavin/flavoprotein donor oxidoreductase
EC: 1.14.14.1
Lineage    Species: Homo sapiens     (Click to Show/Hide the Complete Species Lineage)
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Interactome
Interactions between Xenobiotics and DME (XEOTIC)
      Fungicide(s), Herbicide(s) or Insecticide(s)
                  Pesticide/Insecticide Click to Show/Hide the Full List of Xenobiotics:        3 Xenobiotics
                              Cypermethrin Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01046   XEOTIC Info Gene Form mRNA
                                 Classification Pesticide/Insecticide
                                 DME Modulation Cypermethrin up-regulates the expression of DME CYP2C19 [1]
                              Decamethrin Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01047   XEOTIC Info Gene Form mRNA
                                 Classification Pesticide/Insecticide
                                 DME Modulation Decamethrin up-regulates the expression of DME CYP2C19 [1]
                              Fenvalerate Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01053   XEOTIC Info Gene Form mRNA
                                 Classification Pesticide/Insecticide
                                 DME Modulation Fenvalerate up-regulates the expression of DME CYP2C19 [1]
      Health or Environmental Toxicant(s)
                  Acute Toxic Substance Click to Show/Hide the Full List of Xenobiotics:        1 Xenobiotics
                              Chlorpyrifos Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01248   XEOTIC Info Gene Form mRNA
                                 Classification Acute Toxic Substance
                                 DME Modulation Chlorpyrifos up-regulates the expression of DME CYP2C19 [2]
                  Carcinogen Click to Show/Hide the Full List of Xenobiotics:        1 Xenobiotics
                              Aflatoxin B1 Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00806   XEOTIC Info Gene Form mRNA
                                 Classification Carcinogen-mycotoxin
                                 DME Modulation Aflatoxin B1 inhibits the expression of DME CYP2C19 [3], [4]
                  Environmental Pollutant Click to Show/Hide the Full List of Xenobiotics:        3 Xenobiotics
                              2-tert-butylhydroquinone Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01129   XEOTIC Info Gene Form Protein
                                 Classification Environmental Pollutant
                                 DME Modulation 2-tert-butylhydroquinone induces the drug-metabolizing activity of DME CYP2C19 [5]
                              Diazinon Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01274   XEOTIC Info Gene Form mRNA
                                 Classification Environmental Pollutant
                                 DME Modulation Diazinon up-regulates the expression of DME CYP2C19 [2]
                              N-3-benzylnirvanol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01388   XEOTIC Info Gene Form Protein
                                 Classification Environmental Pollutant
                                 DME Modulation N-3-benzylnirvanol inhibits the drug-metabolizing activity of DME CYP2C19 (IC50 = 0.138 microM) [6]
                  Health Hazard/Toxicant Click to Show/Hide the Full List of Xenobiotics:        1 Xenobiotics
                              Alpha-linolenic acid Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00873   XEOTIC Info Gene Form Protein
                                 Classification Health Hazard
                                 DME Modulation Alpha-linolenic acid inhibits the drug-metabolizing activity of DME CYP2C19 [7]
      Natural Product(s), Extract(s) or Medicine(s)
                  Natural Mixture Click to Show/Hide the Full List of Xenobiotics:        1 Xenobiotics
                              Cyclodextrins Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00857   XEOTIC Info Gene Form Protein
                                 Classification Natural Mixture
                                 DME Modulation Cyclodextrins inhibits the drug-metabolizing activity of DME CYP2C19 [8]
                  Natural Product Click to Show/Hide the Full List of Xenobiotics:      12 Xenobiotics
                              5-methyltryptamine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01518   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation 5-methyltryptamine inhibits the drug-metabolizing activity of DME CYP2C19 [9]
                              7-hydroxyflavone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01176   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation 7-hydroxyflavone inhibits the drug-metabolizing activity of DME CYP2C19 [10]
                              Baicalein Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01212   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation Baicalein inhibits the drug-metabolizing activity of DME CYP2C19 [10]
                              Chrysosplenetin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01529   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation Chrysosplenetin inhibits the drug-metabolizing activity of DME CYP2C19 [10]
                              Dihydrocapsaicin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00802   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation Dihydrocapsaicin inhibits the drug-metabolizing activity of DME CYP2C19 [11]
                              Diosmetin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01281   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation Diosmetin inhibits the drug-metabolizing activity of DME CYP2C19 [12]
                              Eupatorin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01541   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation Eupatorin inhibits the drug-metabolizing activity of DME CYP2C19 [13]
                              Germacrone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01313   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation Germacrone inhibits the drug-metabolizing activity of DME CYP2C19 [14]
                              Hesperetin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00856   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation Hesperetin inhibits the drug-metabolizing activity of DME CYP2C19 [10]
                              Inermin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01345   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation Inermin inhibits the drug-metabolizing activity of DME CYP2C19 [10]
                              Pinostilbene Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01573   XEOTIC Info Gene Form mRNA
                                 Classification Natural Product
                                 DME Modulation Pinostilbene inhibits the expression of DME CYP2C19 [15]
                              Sophoranone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01472   XEOTIC Info Gene Form mRNA
                                 Classification Natural Product
                                 DME Modulation Sophoranone inhibits the expression of DME CYP2C19 [16]
                  Plant Extract Click to Show/Hide the Full List of Xenobiotics:        1 Xenobiotics
                              Salvia extract Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01584   XEOTIC Info Gene Form mRNA
                                 Classification Plant Extract
                                 DME Modulation Salvia extract inhibits the expression of DME CYP2C19 [17]
      Pharmaceutical Agent(s)
                  Approved/Marketed Drug Click to Show/Hide the Full List of Xenobiotics:      45 Xenobiotics
                              Acetaminophen Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00217   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Acetaminophen inhibits the expression of DME CYP2C19 [18]
                              Calcitriol Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00184   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Calcitriol up-regulates the expression of DME CYP2C19 [19]
                              Cannabidiol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00173   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Cannabidiol inhibits the drug-metabolizing activity of DME CYP2C19 [20]
                              Capsaicin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00178   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Capsaicin inhibits the drug-metabolizing activity of DME CYP2C19 [11]
                              Carbamazepine Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00011   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Carbamazepine up-regulates the expression of DME CYP2C19 [21]
                              Chloramphenicol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00220   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Chloramphenicol inhibits the drug-metabolizing activity of DME CYP2C19 [9]
                              Chlorpromazine hydrochloride Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00280   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Chlorpromazine hydrochloride inhibits the drug-metabolizing activity of DME CYP2C19 (IC50 = 34.1 microM) [22]
                              Cyclosporine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00241   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Cyclosporine inhibits the drug-metabolizing activity of DME CYP2C19 (IC50 = 7 microM) [23]
                              Delavirdine mesylate Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00287   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Delavirdine mesylate inhibits the drug-metabolizing activity of DME CYP2C19 [24]
                              Desipramine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00022   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Desipramine inhibits the drug-metabolizing activity of DME CYP2C19 [25]
                              Diethylcarbamazine Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00242   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Diethylcarbamazine induces the drug-metabolizing activity of DME CYP2C19 [26]
                              Efavirenz Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00216   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Efavirenz inhibits the drug-metabolizing activity of DME CYP2C19 [24]
                              Ethambutol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00357   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Ethambutol inhibits the drug-metabolizing activity of DME CYP2C19 [27]
                              Fenofibrate Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00035   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Fenofibrate up-regulates the expression of DME CYP2C19 [17]
                              Fluconazole Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00036   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Fluconazole inhibits the drug-metabolizing activity of DME CYP2C19 (IC50 = 8.2 microM) [9]
                              Fluoxetine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00358   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Fluoxetine inhibits the drug-metabolizing activity of DME CYP2C19 (IC50 = 0.04 microM) [28]
                              Fluphenazine hydrochloride Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00295   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Fluphenazine hydrochloride inhibits the drug-metabolizing activity of DME CYP2C19 [25]
                              Ketoconazole Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00251   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Ketoconazole inhibits the drug-metabolizing activity of DME CYP2C19 (IC50 = 10.1 microM) [29]
                              Lansoprazole Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00052   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Lansoprazole inhibits the drug-metabolizing activity of DME CYP2C19 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 0.3367 microM) [30]
                              Mephenytoin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00060   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Mephenytoin inhibits the drug-metabolizing activity of DME CYP2C19 [31], [32]
                              Miconazole nitrate Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00308   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Miconazole nitrate inhibits the drug-metabolizing activity of DME CYP2C19 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 0.016 microM) [33]
                              Nicardipine hydrochloride Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00311   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Nicardipine hydrochloride inhibits the drug-metabolizing activity of DME CYP2C19 (IC50 = 0.56 microM) [22]
                              Omeprazole Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00069   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Omeprazole inhibits the drug-metabolizing activity of DME CYP2C19 (IC50 = 35 microM) [34]
                              Pentamidine isethionate Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00317   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Pentamidine isethionate inhibits the drug-metabolizing activity of DME CYP2C19 (IC50 > 100 microM) [35]
                              Quinine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00180   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Quinine inhibits the drug-metabolizing activity of DME CYP2C19 [36]
                              Rifampin Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00223   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Rifampin induces the drug-metabolizing activity of DME CYP2C19 [37]
                              Ritonavir Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00160   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Ritonavir up-regulates the expression of DME CYP2C19 [38]
                              Tamoxifen Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00383   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Tamoxifen up-regulates the expression of DME CYP2C19 [39]
                              Thioridazine hydrochloride Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00330   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Thioridazine hydrochloride inhibits the drug-metabolizing activity of DME CYP2C19 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 6.3778 microM) [25]
                              Ticlopidine hydrochloride Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00331   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Ticlopidine hydrochloride inhibits the drug-metabolizing activity of DME CYP2C19 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 0.6678 microM) [14]
                              Tranylcypromine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00385   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Tranylcypromine inhibits the drug-metabolizing activity of DME CYP2C19 (IC50 = 3.04 microM) [40]
                              Troglitazone Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00086   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Troglitazone up-regulates the expression of DME CYP2C19 [41]
                              Valproic acid Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00029   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Valproic acid up-regulates the expression of DME CYP2C19 [17]
                              Voriconazole Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00142   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Voriconazole inhibits the drug-metabolizing activity of DME CYP2C19 (IC50 = 15 microM) [42], [43]
                              Zafirlukast Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00087   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Zafirlukast inhibits the expression of DME CYP2C19 [44]
                              Amodiaquine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00489   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Amodiaquine inhibits the drug-metabolizing activity of DME CYP2C19 (IC50 > 50 microM) [22]
                              Artemisinine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00449   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Artemisinine inhibits the drug-metabolizing activity of DME CYP2C19 [26]
                              Asiaticoside Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00453   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Asiaticoside inhibits the drug-metabolizing activity of DME CYP2C19 [33]
                              Benidipine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00438   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Benidipine inhibits the drug-metabolizing activity of DME CYP2C19 [45]
                              Benzbromarone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00492   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Benzbromarone inhibits the drug-metabolizing activity of DME CYP2C19 (IC50 = 18.2 microM) [22]
                              Cinnamic acid Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01252   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Cinnamic acid inhibits the drug-metabolizing activity of DME CYP2C19 [46]
                              Dihydroartemisinin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00454   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Dihydroartemisinin inhibits the drug-metabolizing activity of DME CYP2C19 [26]
                              Linoleic acid Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01367   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Linoleic acid inhibits the drug-metabolizing activity of DME CYP2C19 [7]
                              Melarsoprol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00475   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Melarsoprol inhibits the drug-metabolizing activity of DME CYP2C19 [47], [48]
                              Mepirodipine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01372   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Mepirodipine inhibits the drug-metabolizing activity of DME CYP2C19 [31]
                  Drug in Phase 3 Clinical Trial Click to Show/Hide the Full List of Xenobiotics:        2 Xenobiotics
                              Resveratrol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00568   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 3
                                 DME Modulation Resveratrol inhibits the drug-metabolizing activity of DME CYP2C19 in Cellosaurus cell line BTI-Tn-5B1-4 (IC50 = 3 microM) [49]
                              Triclosan Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00560   XEOTIC Info Gene Form mRNA
                                 Classification Highest Clinical Status: Phase 3
                                 DME Modulation Triclosan up-regulates the expression of DME CYP2C19 [50]
                  Drug in Phase 2 Clinical Trial Click to Show/Hide the Full List of Xenobiotics:        5 Xenobiotics
                              Bisphenol A Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01226   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation Bisphenol A inhibits the drug-metabolizing activity of DME CYP2C19 [51]
                              Ditiocarb Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00591   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation Ditiocarb inhibits the drug-metabolizing activity of DME CYP2C19 [52]
                              Genistein Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00557   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation Genistein inhibits the drug-metabolizing activity of DME CYP2C19 [10]
                              Icaritin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00653   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation Icaritin inhibits the drug-metabolizing activity of DME CYP2C19 [10]
                              Ursolic acid Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01496   XEOTIC Info Gene Form mRNA
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation Ursolic acid inhibits the expression of DME CYP2C19 [53]
                  Drug in Phase 1 Clinical Trial Click to Show/Hide the Full List of Xenobiotics:        4 Xenobiotics
                              Licochalcone A Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01365   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation Licochalcone A inhibits the drug-metabolizing activity of DME CYP2C19 [54]
                              Luteolin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00537   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation Luteolin inhibits the drug-metabolizing activity of DME CYP2C19 [55]
                              Naringenin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00573   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation Naringenin inhibits the drug-metabolizing activity of DME CYP2C19 [56]
                              Quercetin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00538   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation Quercetin inhibits the drug-metabolizing activity of DME CYP2C19 (IC50 = 10.5 microM) [29]
                  Preclinical/Patented Drug Click to Show/Hide the Full List of Xenobiotics:        4 Xenobiotics
                              CP-778875 Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01156   XEOTIC Info Gene Form Protein
                                 Classification Drug in Preclinical Study
                                 DME Modulation CP-778875 inhibits the drug-metabolizing activity of DME CYP2C19 [57]
                              Isoliquiritigenin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00710   XEOTIC Info Gene Form Protein
                                 Classification Drug in Preclinical Study
                                 DME Modulation Isoliquiritigenin inhibits the drug-metabolizing activity of DME CYP2C19 [10]
                              Miltirone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00708   XEOTIC Info Gene Form Protein
                                 Classification Drug in Preclinical Study
                                 DME Modulation Miltirone inhibits the drug-metabolizing activity of DME CYP2C19 [58]
                              Okanin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00733   XEOTIC Info Gene Form mRNA
                                 Classification Patented Pharmaceutical Agent
                                 DME Modulation Okanin inhibits the expression of DME CYP2C19 [59]
                  Drug Marketed but Withdrawn from Market Click to Show/Hide the Full List of Xenobiotics:        1 Xenobiotics
                              Phencyclidine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01426   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but Withdrawn from Market
                                 DME Modulation Phencyclidine inhibits the drug-metabolizing activity of DME CYP2C19 [60]
                  Investigative Agent Click to Show/Hide the Full List of Xenobiotics:        7 Xenobiotics
                              5-fluorotryptamine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01159   XEOTIC Info Gene Form Protein
                                 Classification Investigative Agent
                                 DME Modulation 5-fluorotryptamine inhibits the drug-metabolizing activity of DME CYP2C19 [9]
                              7-methyltryptamine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01177   XEOTIC Info Gene Form Protein
                                 Classification Investigative Agent
                                 DME Modulation 7-methyltryptamine inhibits the drug-metabolizing activity of DME CYP2C19 [9]
                              Arachidonic acid Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00876   XEOTIC Info Gene Form Protein
                                 Classification Investigative Agent
                                 DME Modulation Arachidonic acid inhibits the drug-metabolizing activity of DME CYP2C19 [7]
                              Avasimibe Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00804   XEOTIC Info Gene Form Protein
                                 Classification Investigative Agent
                                 DME Modulation Avasimibe inhibits the drug-metabolizing activity of DME CYP2C19 [61]
                              Beta-naphthoflavone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01220   XEOTIC Info Gene Form mRNA
                                 Classification Investigative Agent
                                 DME Modulation Beta-naphthoflavone inhibits the expression of DME CYP2C19 [62]
                              DY-9760e Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01130   XEOTIC Info Gene Form Protein
                                 Classification Investigative Agent
                                 DME Modulation DY-9760e inhibits the drug-metabolizing activity of DME CYP2C19 [63]
                              N-3-benzylphenobarbital Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01389   XEOTIC Info Gene Form Protein
                                 Classification Investigative Agent
                                 DME Modulation N-3-benzylphenobarbital inhibits the drug-metabolizing activity of DME CYP2C19 (Ki = 79 microM) [64]
References
1 Characterization of human cytochrome P450 induction by pesticides. Toxicology. 2012 Mar 29;294(1):17-26.
2 Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology. 2006 Jul 5;224(1-2):22-32.
3 Identification of early target genes of aflatoxin B1 in human hepatocytes, inter-individual variability and comparison with other genotoxic compounds. Toxicol Appl Pharmacol. 2012 Jan 15;258(2):176-87.
4 Aflatoxin B1 induces persistent epigenomic effects in primary human hepatocytes associated with hepatocellular carcinoma. Toxicology. 2016 Mar 28;350-352:31-9.
5 Regulation of human CYP2C9 expression by electrophilic stress involves activator protein 1 activation and DNA looping. Mol Pharmacol. 2014 Aug;86(2):125-37.
6 Discovery of biphenyl imidazole derivatives as potent antifungal agents: Design, synthesis, and structure-activity relationship studies. Bioorg Med Chem. 2017 Jan 15;25(2):750-758.
7 The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
8 Interaction of modified cyclodextrins with cytochrome P-450. Biosci Biotechnol Biochem. 2005 Jan;69(1):246-8.
9 Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
10 Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
11 Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
12 Effects of diosmetin on nine cytochrome P450 isoforms, UGTs and three drug transporters in vitro. Toxicol Appl Pharmacol. 2017 Nov 1;334:1-7.
13 In vitro modulatory effects of Andrographis paniculata, Centella asiatica and Orthosiphon stamineus on cytochrome P450 2C19 (CYP2C19). J Ethnopharmacol. 2011 Jan 27;133(2):881-7.
14 Interactions of sesquiterpenes zederone and germacrone with the human cytochrome P450 system. Toxicol In Vitro. 2013 Sep;27(6):2005-12.
15 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
16 Global alteration of gene expression in human keratinocytes by inorganic arsenic. Carcinogenesis. 2003 Apr;24(4):747-56.
17 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
18 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
19 Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor. J Steroid Biochem Mol Biol. 2016 Oct;163:77-87.
20 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
21 Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 2006 Nov;80(5):440-456.
22 Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors. Drug Metab Dispos. 2013 Jan;41(1):60-71.
23 SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother. 2010 Feb;54(2):660-72.
24 Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001 Jan;41(1):85-91.
25 Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
26 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
27 Inhibition of cytochrome P450 by ethambutol in human liver microsomes. Toxicol Lett. 2014 Aug 17;229(1):33-40.
28 Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). Eur J Med Chem. 2015 Oct 20;103:210-22.
29 Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug Metab Dispos. 2012 May;40(5):943-51.
30 The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos. 2011 Nov;39(11):2020-33.
31 Anti-cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF-B. Prostate. 2011 Jun 1;71(8):801-12.
32 Melittin suppresses VEGF-A-induced tumor growth by blocking VEGFR-2 and the COX-2-mediated MAPK signaling pathway. J Nat Prod. 2012 Nov 26;75(11):1922-9.
33 In vitro inhibitory effects of asiaticoside and madecassoside on human cytochrome P450. Toxicol In Vitro. 2011 Jun;25(4):890-6.
34 Novel terminal bipheny-based diapophytoene desaturases (CrtN) inhibitors as anti-MRSA/VISR/LRSA agents with reduced hERG activity. J Med Chem. 2018 Jan 11;61(1):224-250.
35 Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds. Eur J Med Chem. 2017 Jan 27;126:1129-1135.
36 Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells. Biochem Pharmacol. 2004 Apr 15;67(8):1607-17.
37 Impact of trans-resveratrol-sulfates and -glucuronides on endothelial nitric oxide synthase activity, nitric oxide release and intracellular reactive oxygen species. Molecules. 2014 Oct 17;19(10):16724-36.
38 Methionine adenosyltransferase 2B, HuR, and sirtuin 1 protein cross-talk impacts on the effect of resveratrol on apoptosis and growth in liver cancer cells. J Biol Chem. 2013 Aug 9;288(32):23161-70.
39 Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer. 2008 Mar 1;122(5):990-8.
40 Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. J Med Chem. 2008 Apr 10;51(7):2158-69.
41 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
42 Breakthrough Candida infections in patients receiving voriconazole. Ann Pharmacother. 2005 Jul-Aug;39(7-8):1342-5.
43 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
44 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
45 Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
46 Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity. J Mol Endocrinol. 2004 Apr;32(2):425-36.
47 Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chem Biol Interact. 2003 Feb 1;143-144:503-13.
48 Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
49 Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun Mass Spectrom. 2003;17(4):307-13.
50 Organophosphorus flame retardants impair intracellular lipid metabolic function in human hepatocellular cells. Chem Res Toxicol. 2019 Jun 17;32(6):1250-1258.
51 Inhibition of drug-metabolizing enzyme activity in human hepatic cytochrome P450s by bisphenol A. Biol Pharm Bull. 2000 Apr;23(4):498-501.
52 Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica. 1996 Jul;26(7):681-93.
53 Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology. 2006 Jan;43(1):134-43.
54 Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice. Toxicol In Vitro. 2015 Oct;29(7):1569-76.
55 The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79.
56 Curcumin is a tight-binding inhibitor of the most efficient human daunorubicin reductase--Carbonyl reductase 1. Chem Biol Interact. 2015 Jun 5;234:162-8.
57 Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated receptor alpha. Xenobiotica. 2013 Nov;43(11):963-72.
58 In the search for specific inhibitors of human 11beta-hydroxysteroid-dehydrogenases (11beta-HSDs): chenodeoxycholic acid selectively inhibits 11beta-HSD-I. Eur J Endocrinol. 2000 Feb;142(2):200-7.
59 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
60 Inhibition of human and rat 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 activities by perfluoroalkylated substances. Chem Biol Interact. 2010 Oct 6;188(1):38-43.
61 Effects of avasimibe on cytochrome P450 2C9 expression in vitro and in vivo. Drug Metab Dispos. 2004 Dec;32(12):1370-6.
62 Differentiation-specific factors modulate epidermal CYP1-4 gene expression in human skin in response to retinoic acid and classic aryl hydrocarbon receptor ligands. J Pharmacol Exp Ther. 2006 Dec;319(3):1162-71.
63 In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions. Drug Metab Dispos. 2005 Nov;33(11):1628-36.
64 The metabolism of CYP2C9 and CYP2C19 for gliclazide by homology modeling and docking study. Eur J Med Chem. 2009 Feb;44(2):854-61.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.